الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 99 |  |  |
| | | from | 99 | | |
Abstract
Acute leukemia is a condition characterized by uncontrolled clonal proliferation of abnormal bone marrow and blood cells. It is classified into acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) based on morphologic diagnosis.
AML is more common in adults and has various risk factors, including myelodysplastic syndrome, environmental exposures, genetic mutations, and previous exposure to chemotherapy. It is associated with specific genetic alterations and mutations. Nucleophosmin 1 (NPM1) and Fms-like tyrosine kinase 3 (FLT3) are important genes involved in AML.
ALL, on the other hand, is more common in children and has various risk factors, including genetic mutations andviral infections. Both AML and ALL have specific diagnostic procedures and classifications.
The treatment of AML involves intensive chemotherapy and consolidation therapy, while the treatment of ALL involves induction of remission, consolidation, and maintenance therapy. Novel targeted therapies, such as inhibitors of mutated FLT3 and IDH1/IDH2, as well as immunotherapies, are being explored for the treatment of AML and ALL.